Human infection with a highly pathogenic avian influenza a (H5N6) virus in yunnan province, China

Infectious Diseases

Volumn 48, Issue 6, 2016, Pages 477-482

  Xu, Wen ^a   Li, Hong ^a   Jiang, Li ^a  

^a YUNNAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

H5N6; Highly pathogenic avian influenza; Virological analysis

Indexed keywords

ALBUMIN; AMANTADINE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; ARGININE; GLUCOCORTICOID; HEMAGGLUTININ; PROTEIN M2; SIALIDASE INHIBITOR; VIRUS RNA;

ADAPTATION; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANAS PLATYRHYNCHOS; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ARTIFICIAL VENTILATION; ASTHENIA; CAGE; CASE REPORT; CHICKEN LUNG TISSUE; CHINA; CLADISTICS; COUGHING; CRACKLE; DISEASE SURVEILLANCE; DYSPNEA; FECES; FEVER; FLU LIKE SYNDROME; GENETIC TRAIT; HEADACHE; HIGHLY PATHOGENIC AVIAN INFLUENZA; HUMAN; INFLUENZA A (H5N6); LUNG PARENCHYMA; MALE; MAMMAL; MAMMALIAN ADAPTATION; MARKET; MULTIPLE ORGAN FAILURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PHYSICAL EXAMINATION; PNEUMONIA; POULTRY; POULTRY FECES; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEWAGE; SORE THROAT; THORAX PAIN; THORAX RADIOGRAPHY; THROAT CULTURE; TRACHEAL ASPIRATION PROCEDURE; URBAN AREA; VIRUS IDENTIFICATION; VIRUS STRAIN; WETLAND; ANIMAL; AVIAN INFLUENZA; BIRD; BIRD DISEASE; FATALITY; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; VIROLOGY;

ADULT; ANIMALS; ANTIVIRAL AGENTS; BIRDS; CHINA; DRUG RESISTANCE, VIRAL; FATAL OUTCOME; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; MALE; POULTRY DISEASES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 84968546902     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1135253     Document Type: Review

References (21)

1. Sonnberg S, Webby RJ, Webster RG. Natural history of highly pathogenic avian influenza H5N1. Virus Res. 2013;178:63-77.
2. Smith GJ, Donis RO, World Health Organization/World Organisation for Animal Health/Food and Agriculture Organization H5 Evolution Working Group. Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013-2014. Influenza Other Respir Viruses. 2015;9:271-276.
3. Food and Agriculture Organization of the United Nations (FAO). Avian influenza A(H5N6): the latest addition to emerging zoonotic avian influenza threats in East and Southeast Asia. EMPRES WATCH. 2014;30:1-5.
4. Pan M, Gao R, Lv Q, et al. Human infection with a novel highly pathogenic avian influenza A (H5N6) virus: Virological and clinical findings. J Infect. 2015;72:52-59
5. Yang ZF, Mok CK, Peiris JS, Zhong NS. Human Infection with a Novel Avian Influenza A(H5N6) Virus. N Engl J Med. 2015;373:487-489
6. Harvey R, Martin AC, Zambon M, Barclay WS. Restrictions to the adaptation of influenza a virus h5 hemagglutinin to the human host. J Virol. 2004;78:502-507.
7. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother. 2005;49:4515-4520.
8. Stoner TD, Krauss S, Turner JC, et al. Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir. Antiviral Res. 2012;93:322-329.
9. Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002;54:79-88.
10. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-765.
11. Gabriel G, Czudai-Matwich V, Klenk HD. Adaptive mutations in the H5N1 polymerase complex. Virus Res. 2013;178:53-62.
12. Herfst S, Schrauwen EJ, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science. 2012;336:1534-1541
13. Song MS, Pascua PN, Lee JH, et al. The polymerase acidic protein gene of influenza a virus contributes to pathogenicity in a mouse model. J Virol. 2009;83:12325-12335.
14. Fan S, Deng G, Song J, et al. Two amino acid residues in the matrix protein M1 contribute to the virulence difference of H5N1 avian influenza viruses in mice. Virology. 2009;384:28-32.
15. Gleed ML, Busath DD. Why bound amantadine fails to inhibit proton conductance according to simulations of the drug-resistant influenza A M2 (S31N). J Phys Chem B. 2015;119:1225-1231.
16. Jiao P, Tian G, Li Y, et al. A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. J Virol. 2008;82:1146-1154.
17. Wang C, Yu H, Horby PW, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis. 2014;58:1095-1103.
18. Li J, Zu Dohna H, Cardona CJ, et al. Emergence and genetic variation of neuraminidase stalk deletions in avian influenza viruses. PLoS One. 2011;6:e14722.
19. Baigent SJ, McCauley JW. Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture. Virus Res. 2001;79:177-185.
20. Matsuoka Y, Swayne DE, Thomas C, et al. Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice. J Virol. 2009;83:4704-4708.
21. Kilpatrick AM, Chmura AA, Gibbons DW, et al. Predicting the global spread of H5N1 avian influenza. Proc Natl Acad Sci USA. 2006;103:19368-19373